Sterner et al. studied granulocyte-macrophage colony-stimulating factor (GM-CSF) disruption by CRISPR/Cas9 in preclinical murine models and showed that neutralizing GM-CSF by lenzilumab is a potential strategy to abrogate CD19-CAR-T-related CRS without inhibition of CAR T cell function [260]. This evidence concerns the gene CSF2 and congenital rubella syndrome.